VRNA Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.4%, SMA50 0.92%, SMA200 35.92%). The stock’s 14-day RSI is 72.54 (overbought), while the ATR of 0.23 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.02% below its high and over 243.87% above its low.

Verona Pharma plc has 84.98 million shares outstanding. The public float is 564.82 million shares, elevated short interest at 2.42% of float. This equals 2.01 million shares. The short ratio is 1.34 days. Institutional investors hold 99.9% of the float. Insiders own 4.89%. Blavatnik Len holds 55.91 million shares, Access Industries Holdings LLC has 55.91 million shares and ZACCARDELLI DAVID has 13.38 million shares.

Verona Pharma plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $35.19. This means the shares are trading above this model’s fair value.

Verona Pharma plc generated EPS of -$1.03 over the past year. Five-year average earnings growth is 7.21%. The latest quarter delivered EPS of -$0.56. The next quarter is forecast at $0.01. Next year's EPS is expected at -$27.72. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 3 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $170.00 to $72.00. The high target offers 59.01% upside. The low target suggests -32.65% downside. The mean target is $112.67. This offers 5.39% upside. Verona Pharma plc earnings surprise history is frequent misses against expectations. The quarter that ended November 03, 2025, missed forecasts by -450.0%. The prior quarter beat by -1400.0%. Over the last six quarters, Apple has recorded several small beats. These include -60.48% in August 08, 2024.

Verona Pharma plc (NASDAQ:VRNA) shares are up 130.21% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Verona Pharma plc trading at a premium to the broader market with a P/E of -145.11. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $55.40, suggesting -48.18% downside. Our AI forecast model points to short-term strength (0.28% over two weeks), a medium-term rise (0.94% over three months), and a longer-term gain (29.36% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Verona Pharma plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.28%, with price expected at $107.21 by October 20, 2025, within a range of $103.22 to $111.17 3-Month Outlook: Projected rise of 0.94%, reaching $107.91 by January 02, 2026, with a range of $104.91 to $110.91. 1-Year Outlook: Projected gain of 29.36%, with price at $138.30 by October 06, 2026, within a range of $132.68 to $144.52.

Verona Pharma plc (NASDAQ:VRNA) closed at $106.91 USD, gaining $0.12 (0.11%) from the previous close of $106.79. The stock is currently trading near its 52-week high $31.09 and $106.93. With a market capitalization of about $72.68 billion, Verona Pharma plc is classified as a large-cap and shows lower-than-market volatility (beta ~0.05). Key stats such as the average daily volume over the past year has been around 3.56 million shares, volume is running light vs its 52-week average. Headquartered in London, None, Verona Pharma plc operates in the Healthcare sector and the Biotechnology industry. Led by CEO David S. Zaccardelli, the company employs approximately 209 people and listed since April 28, 2017. Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.

Verona Pharma plc trades at a P/E ratio of -145.11, slightly below the S&P 500 average, with a price-to-sales ratio of 433.52 and a price-to-book ratio of 32.9 reflecting a rich premium to book value. The P/FCF stands at -995.27, also below market averages. Compared to sector medians, Verona Pharma plc P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.